Walmsley’s Dream Hire Badly Needs to Find Some Blockbuster Drugs

The article discusses Emma Walmsley's hiring of Luke Miels as a key executive at GSK Plc. Nearly nine years ago, when Walmsley was preparing to become the CEO of GSK, she expressed in her diary that Miels, who was then an executive at AstraZeneca Plc, would be an ideal appointment for her "adventure" at GSK. However, the article suggests that Miels, who was Walmsley's "dream hire," is now in desperate need of finding some blockbuster drugs for GSK. The company has faced challenges in developing new, innovative medicines, and Miels, as the head of the pharmaceutical business, is under pressure to deliver successful drug candidates to the market. The article highlights the importance of Miels' role in reviving GSK's drug pipeline and the high expectations placed on him by Walmsley and the company's investors. The success or failure of Miels in this endeavor will likely have a significant impact on Walmsley's legacy as the CEO of GSK.